Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Testing effectiveness (Phase 2)Looking for participantsNCT01473628
What this trial is testing

Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma

Who this might be right for
Ann Arbor Stage I Grade 1 Follicular LymphomaAnn Arbor Stage I Grade 2 Follicular LymphomaAnn Arbor Stage II Grade 1 Follicular Lymphoma+1 more
M.D. Anderson Cancer Center 130
Early research (Phase 1)Active Not RecruitingNCT01829568
What this trial is testing

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

Who this might be right for
Ann Arbor Stage II Grade 1 Contiguous Follicular LymphomaAnn Arbor Stage II Grade 1 Non-Contiguous Follicular LymphomaAnn Arbor Stage II Grade 2 Contiguous Follicular Lymphoma+9 more
National Cancer Institute (NCI)
Large-scale testing (Phase 3)Ended earlyNCT02320292
What this trial is testing

Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma

Who this might be right for
Ann Arbor Stage I Grade 1 Follicular LymphomaAnn Arbor Stage I Grade 2 Follicular LymphomaAnn Arbor Stage II Grade 1 Contiguous Follicular Lymphoma+7 more
Mayo Clinic 20
Testing effectiveness (Phase 2)Study completedNCT01145495
What this trial is testing

Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Who this might be right for
Ann Arbor Stage II Grade 1 Contiguous Follicular LymphomaAnn Arbor Stage II Grade 1 Non-Contiguous Follicular LymphomaAnn Arbor Stage II Grade 2 Contiguous Follicular Lymphoma+9 more
National Cancer Institute (NCI) 66
Testing effectiveness (Phase 2)Study completedNCT00105001
What this trial is testing

Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Who this might be right for
Myelodysplastic/Myeloproliferative Neoplasm, UnclassifiablePreviously Treated Myelodysplastic SyndromeRefractory Chronic Lymphocytic Leukemia+113 more
Fred Hutchinson Cancer Center 210
Testing effectiveness (Phase 2)Active Not RecruitingNCT02494700
What this trial is testing

Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma

Who this might be right for
Ann Arbor Stage I B-Cell Non-Hodgkin LymphomaAnn Arbor Stage I Grade 1 Follicular LymphomaAnn Arbor Stage I Grade 2 Follicular Lymphoma+20 more
M.D. Anderson Cancer Center 50
Testing effectiveness (Phase 2)Study completedNCT02871219
What this trial is testing

Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma

Who this might be right for
Ann Arbor Stage II Grade 1 Follicular LymphomaAnn Arbor Stage II Grade 2 Follicular LymphomaAnn Arbor Stage III Grade 1 Follicular Lymphoma+10 more
M.D. Anderson Cancer Center 96
Not applicableStudy completedNCT01057459
What this trial is testing

DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701

Who this might be right for
Lymphoma
Alliance for Clinical Trials in Oncology 78
33